MétaCan
Menu
Back to cohort

Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention

2019· review· en· W2973068166 on OpenAlexafffund
Philip Urban, Roxana Mehran, Róisín Colleran, Dominick J. Angiolillo, Robert A. Byrne, Davide Capodanno, Thomas Cuisset, Donald E. Cutlip, Pedro Eerdmans, John W. Eikelboom, Andrew Farb, C. Michael Gibson, John Gregson, Michael Haude, Stefan James, Hyo‐Soo Kim, Takeshi Kimura, Akihide Konishi, John C. Laschinger, Martin B. Leon, Patrick Magee, Yoshiaki Mitsutake, Darren Mylotte, Stuart Pocock, Matthew J. Price, Sunil V. Rao, Ernest Spitzer, Norman Stockbridge, Marco Valgimigli, Olivier Varenne, Ute Windhoevel, Robert W. Yeh, Mitchell W. Krucoff, Marie-Claude Morice

Bibliographic record

VenueCirculation · 2019
Typereview
Languageen
FieldMedicine
TopicAntiplatelet Therapy and Cardiovascular Diseases
Canadian institutionsMcMaster University123 Certification (Canada)
FundersJanssen PharmaceuticalsNational Center for Advancing Translational SciencesAbbott VascularSt. Jude MedicalNational Institutes of HealthIdorsia PharmaceuticalsDaiichi Sankyo EuropeGilead SciencesServierEisaiSanofiAbiomedOsprey MedicalChiesi USAClaret MedicalBiosense WebsterNovo NordiskDaiichi-SankyoMedicines CompanyCook MedicalBoston Scientific CorporationBristol-Myers SquibbEli Lilly and CompanyAstraZenecaAbbott LaboratoriesCSL BehringUniversity of FloridaB. Braun MelsungenAmgenPfizerMedicure
KeywordsMedicinePercutaneous coronary interventionClinical trialPopulationGuidelineRegulatory affairsIntensive care medicineMedical emergencyMyocardial infarctionInternal medicineEnvironmental healthPathologyPublic administration

Abstract

fetched live from OpenAlex

Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of standardization in defining this population limits trial design, data interpretation, and clinical decision-making. The Academic Research Consortium for High Bleeding Risk (ARC-HBR) is a collaboration among leading research organizations, regulatory authorities, and physician-scientists from the United States, Asia, and Europe focusing on percutaneous coronary intervention-related bleeding. Two meetings of the 31-member consortium were held in Washington, DC, in April 2018 and in Paris, France, in October 2018. These meetings were organized by the Cardiovascular European Research Center on behalf of the ARC-HBR group and included representatives of the US Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, as well as observers from the pharmaceutical and medical device industries. A consensus definition of patients at high bleeding risk was developed that was based on review of the available evidence. The definition is intended to provide consistency in defining this population for clinical trials and to complement clinical decision-making and regulatory review. The proposed ARC-HBR consensus document represents the first pragmatic approach to a consistent definition of high bleeding risk in clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing percutaneous coronary intervention.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.008
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.005
Threshold uncertainty score0.024

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.008
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.002
Bibliometrics0.0040.003
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.284
Teacher spread0.262 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations796
Published2019
Admission routes2
Has abstractyes

Explore more

Same venueCirculationSame topicAntiplatelet Therapy and Cardiovascular DiseasesFrench-language works237,207